Immuneering Corp
Company Stats
- Market Cap
- $264.9M
- as of Sep 30, 2026
- Shares Outstanding
- 64.7M
- Free Float
- 79.7%
Income Statement
- Operating Income
- -$59.4M
- Net Income
- -$56.0M
- EBITDA
- -$59.1M
Cash Flow
- Free Cash Flow
- -$45.5M
- FCF Yield
- -17.2%
- Owner FCF Yield
- -19.6%
Balance Sheet
- Cash & Equivalents
- $128.6M
Returns & Capital
- SBC, 3Y Avg
- $6.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$45.5M | — |
| FY2024 | — | -$55.1M | — |
| FY2023 | $0 | -$49.3M | — |
| FY2022 | $316,952 | -$44.8M | -14148.4% |
| FY2021 | $2.1M | -$30.9M | -1486.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Input Costs Squeeze Margins Even as Demand Holds Firm